Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| 9979 | ETCTN | Phase 1 and Pharmacology Study of Oral 5-iodo-2-pyrimidinone-2-deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 9984 | ETCTN | A Randomized Phase 2 Study of cediranib in Combination with olaparib versus olaparib alone in men with metastatic castration resistant prostate cancer | Adult CIRB - Early Phase Emphasis | Available to Open | |
| A011106 | Alliance | ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study | Adult CIRB - Late Phase Emphasis | Available to Open | |
| A011202 | Alliance | A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy | Adult CIRB - Late Phase Emphasis | Available to Open | |
| A011203 | Alliance | A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women with Metastatic; Estrogen Receptor Positive; HER2 Negative Breast Cancer | Adult CIRB - Early Phase Emphasis | Available to Open | |
| A011401 | Alliance | Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer | Adult CIRB - Late Phase Emphasis | Available to Open | |
| A011502 | Alliance | A Randomized Phase III Double Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial | Adult CIRB - Late Phase Emphasis | Available to Open | |
| A011801 | Alliance | The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinb | Adult CIRB - Late Phase Emphasis | Available to Open | |
| A012103 | Alliance | OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy | Adult CIRB - Late Phase Emphasis | Available to Open | |
| A012301 | Alliance | LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |